District court’s grant of a preliminary injunction against defendant from manufacturing generic version of a drug for treating respiratory diseases, and finding plaintiff’s kit claims invalid

Astrazeneca LP v. Apotex, Inc., 09-1381, concerned a challenge to the district court’s grant of a preliminary injunction barring defendant from launching a generic version of a budesonide drug for treating respiratory diseases, made and distributed under the approval of the United States Food and Drug Administration (FDA) by plaintiff and covered under method and kit claims in plaintiff’s patents, and determination that the kit claims are invalid.

Related Link:

  • Read the Federal Circuit’s Full Decision in Astrazeneca LP v. Apotex, Inc., 09-1381

You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help

Civil Rights

Block on Trump’s Asylum Ban Upheld by Supreme Court

Criminal

Judges Can Release Secret Grand Jury Records

Politicians Can’t Block Voters on Facebook, Court Rules